Table 3.
Basic information about the included studies.
| Author/year | Number of case | Sex (Men/Women) | Age | EG | CG | Outcome indicator | |||
|---|---|---|---|---|---|---|---|---|---|
| EG | CG | EG | CG | EG | CG | ||||
| Chen and Zhao 2019[10] | 90 | 90 | 43/47 | 52/38 | 52.5 ± 6.9 | 52.5 ± 2.1 | A + C | D | a + b |
| Gu and Zhu 2018[11] | 29 | 29 | 18/11 | 21/8 | 54.27 ± 12.31 | 55.14 ± 10.72 | A + F | F | b |
| Pang, et al 2019[12] | 63 | 63 | 27/36 | 30/33 | 55.10 ± 3.10 | 55.30 ± 2.48 | A + D | D | d |
| Qiao and Lian 2003[13] | 35 | 23 | 14/21 | 14/11 | 48.5 ± 7.5 | 46.5 ± 9.5 | A + D | D | b |
| Ren 2018[14] | 40 | 40 | 29/11 | 28/12 | 54.34 ± 12.42 | 54.27 ± 12.38 | B + D | D | a |
| Wang, et al 2018[15] | 43 | 43 | 23/20 | 26/17 | 52.85 ± 11.40 | 50.27 ± 12.85 | A + F + D | F + D | a + c + d |
| Wang 2019[16] | 37 | 37 | 20/17 | 21/16 | 43.12 ± 1.12 | 43.15 ± 1.14 | B + D | D | a + c + d |
| Wu, et al 2019[17] | 29 | 29 | 18/11 | 17/12 | 50.7 ± 13.9 | 50.6 ± 13.8 | B + D | D | a |
| Xing 2016[18] | 50 | 50 | 26/24 | 31/19 | 36.38 ± 14.05 | 37.65 ± 13.14 | A + D | D | a + c + d |
| Xu 2013[19] | 30 | 30 | 18/12 | 19/11 | 22.10 ± 11.12 | 21.15 ± 12.35 | A + D | D | a |
| Yao 2017[20] | 40 | 40 | 21/19 | 20/20 | 36.4 ± 14.1 | 37.2 ± 14.0 | A + F | F | a + b |
| Zhou, et al 2017[21] | 65 | 65 | 39/26 | 40/25 | 48.65 ± 9.64 | 48.97 ± 8.67 | B + D | D | a + c |
| Zhu 2021[22] | 33 | 33 | 19/14 | 18/15 | 48.29 ± 5.64 | 48.91 ± 5.69 | A + D | D | a + c |
A: Chinese medicine retention enema; B: Oral or nasal administration of Chinese medicines; C: Somatostatin; D: Conventional treatment with western-style medicine; F: blood purification therapy; a: Overall response rate; b: Length of hospital stays; c: Serum TNF-a levels; d: Serum IL-6 levels.
CG = control group, EG = experimental group.